There is increasing evidence that infection with the Epstein-Barr virus (EBV) plays a role in the development of multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the CNS. This article provides a four-tier hypothesis proposing (1) EBV infection is essential for the development of MS; (2) EBV causes MS in genetically susceptible individuals by infecting autoreactive B cells, which seed the CNS where they produce pathogenic autoantibodies and provide costimulatory survival signals to autoreactive T cells that would otherwise die in the CNS by apoptosis; (3) the susceptibility to develop MS after EBV infection is dependent on a genetically determined quantitative deficiency of the cytotoxic CD8+ T cells that normally keep EBV infection under tight control; and (4) sunlight and vitamin D protect against MS by increasing the number of CD8+ T cells available to control EBV infection. The hypothesis makes predictions that can be tested, including the prevention and successful treatment of MS by controlling EBV infection.
AchesonEDBachrachCAWrightFM. 1960. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand Suppl35:132–47.
2.
AmadoriAZamarchiRDe SilvestroGForzaGCavattonGDanieliGA and others. 1995. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med1:1279–83.
3.
AntelJPPeeplesDMRederATArnasonBGW. 1984. Analysis of T regulator cell surface markers and functional properties in multiple sclerosis. J Neuroimmunol6:93–103.
4.
ArmengolMPJuanMLucas-MartínAFernández-FiguerasMTJaraquemadaDGallartT and others. 2001. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol159:861–73.
5.
AscherioAMungerKL. 2007. Environmental risk factors for multiple sclerosis: Part I. The role of infection. Ann Neurol61:288–99.
6.
AscherioAMungerKLLennetteETSpiegelmanDHernánMAOlekMJ and others. 2001. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA286:3083–8.
7.
BachM-APhan-Dinh-TuyFTournierEChatenoudLBachJ-FMartinC and others. 1980. Deficit of suppressor T cells in active multiple sclerosis. Lancet316:1221–3.
8.
BanwellBKruppLKennedyJTellierRTenembaumSNessJ and others. 2007. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol6:773–81.
9.
BechELyckeJGadebergPHansenHJMalmeströmCAndersenO and others. 2002. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology58:31–6.
10.
BecklundBRSeversonKSVangSVDeLucaHF. 2010. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci U S A107:6418–23.
11.
BoossJEsiriMMTourtellotteWWMasonDY. 1983. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci62:219–32.
12.
BrayPFBloomerLCSalmonVCBagleyMHLarsenPD. 1983. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol40:406–8.
13.
BrennanRMBurrowsJMBellMJBromhamLCsurhesPALenarczykA and others. 2010. Strains of Epstein-Barr virus infecting multiple sclerosis patients. Multiple Sclerosis16:643–51.
14.
ÇakmakFNErolMErgülPYalçýnerA. 1999. T lymphocytes and vitamins. J Pediatr135:531.
15.
CepokSZhouDSrivastavaRNesslerSSteiSBüssowK and others. 2005. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest115:1352–60.
16.
ConfavreuxCVukusicS. 2006. Age at disability milestones in multiple sclerosis. Brain129:595–605.
17.
CorrealeJFiolMGilmoreW. 2006. The risk of relapses in multiple sclerosis during systemic infections. Neurology67:652–9.
18.
CraigJCHaireMMerrettJD. 1988. T-cell-mediated suppression of Epstein-Barr virus-induced B lymphocyte activation in multiple sclerosis. Clin Immunol Immunopathol48:253–60.
19.
FalkenbachASedlmeyerA. 1997. Travel to sunny countries is associated with changes in immunological parameters. Photodermatol Photoimmunol Photomed13:139–42.
20.
FarrellRAAntonyDWallGRClarkDAFisnikuLSwantonJ and others. 2009. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology73:32–8.
21.
FerreiraMARManginoMBrummeCJZhaoZZMedlandSEWrightMJ and others. 2010. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet86:88–92.
22.
FraserKBMillarJHDHaireMMcCreaS. 1979. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet314:715–7.
23.
GaleaIBernardes-SilvaMForsePAvan RooijenNLiblauRSPerryVH. 2007. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med204:2023–30.
24.
GoldbergP. 1974. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint): Part 1. Sunlight, dietary factors and epidemiology. Int J Environ Stud6:19–27.
25.
GrantWB. 2008. Hypothesis—ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. Photochem Photobiol84:356–65.
HaahrSHöllsbergP. 2006. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol16:297–310.
28.
HadinotoVShapiroMGreenoughTCSullivanJLLuzuriagaKThorley-LawsonDA. 2008. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood111:1420–7.
29.
HadinotoVShapiroMSunCCThorley-LawsonDA. 2009. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog5:e1000496.
30.
HallMAAhmadiKRNormanPSniederHMacGregorAJVaughanRW and others. 2000. Genetic influence on peripheral blood T lymphocyte levels. Genes Immun1:423–7.
31.
HaqueTJohannessenIDombagodaDSenguptaCBurnsDMBirdP and others. 2006. A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. J Infect Dis194:584–7.
32.
HauserSLBhanAKGillesFKempMKerrCWeinerHL. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol19:578–87.
33.
HauserSLWaubantEArnoldDLVollmerTAntelJFoxRJ and others. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med358:676–88.
34.
HerseyPBradleyMHasicEHaranGEdwardsAMcCarthyWH. 1983a. Immunological effects of solarium exposure. Lancet321:545–8.
35.
HerseyPHaranGHasicEEdwardsA. 1983b. Alteration of T cell subsets and induction of suppressor T cell activity in normal subjects after exposure to sunlight. J Immunol31:171–4.
36.
HislopADTaylorGSSauceDRickinsonAB. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol25:587–617.
37.
HochbergDSouzaTCatalinaMSullivanJLLuzuriagaKThorley-LawsonDA. 2004. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol78:5194–204.
38.
HolmøyT. 2008. Vitamin D status modulates the immune response to Epstein Barr virus: synergistic effect of risk factors in multiple sclerosis. Med Hypotheses70:66–9.
39.
HoshinoYMorishimaTKimuraHNishikawaKTsurumiTKuzushimaK. 1999. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection. J Immunol163:5735–40.
40.
JaquiéryEJilekSSchluepMMeylanPLysandropoulosAPantaleoG and others. 2010. Intrathecal immune responses to EBV in early MS. Eur J Immunol40:878–87.
41.
JilekSSchluepMMeylanPVingerhoetsFGuignardLMonneyA and others. 2008. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain131:1712–21.
42.
KellyGLLongHMStylianouJThomasWALeeseABellAI and others. 2009. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog5:e1000341.
43.
KreuzfelderEShenGBittorfMScheiermannNThraenhartOSeidelD and others. 1992. Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls. Eur Neurol32:190–4.
44.
LaichalkLLThorley-LawsonDA. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol79:1296–307.
45.
LangHLJacobsenHIkemizuSAnderssonCHarlosKMadsenL and others. 2002. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol3:940–3.
46.
LemireJMArcherDC. 1991. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest87:1103–7.
47.
LevinLIMungerKLO’ReillyEJFalkKIAscherioA. 2010. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol67:824–30.
48.
LevinLIMungerKLRubertoneMVPeckCALennetteETSpiegelmanD and others. 2005. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA293:2496–500.
49.
LiNThompsonSSchultzDCZhuWJiangHLuoC and others. 2010. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One5:e10126.
50.
LünemannJDEdwardsNMuraroPAHayashiSCohenJIMünzC and others. 2006. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain129:1493–506.
51.
LünemannJDHuppkePRobertsSBrückWGärtnerJMünzC. 2008a. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology71:1033–5.
52.
LünemannJDJelčićIRobertsSLutterottiATackenbergBMartinR and others. 2008b. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-g and IL-2. J Exp Med205:1763–73.
53.
LünemannJDTintoréMMessmerBStrowigTRoviraAPerkalH and others. 2010. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol67:159–69.
54.
LyckeJSvennerholmBHjelmquistEFrisenLBadrGAnderssonM and others. 1996. Acyclovir treatment of relapsing-remitting multiple sclerosis: a randomized, placebo-controlled, double-blind study. J Neurol243:214–24.
55.
MagliozziRHowellOVoraASerafiniBNicholasRPuopoloM and others. 2007. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain130:1089–104.
56.
MancaoCHammerschmidtW. 2007. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood110:3715–21.
57.
McCarthyNJHazlewoodSAHuenDSRickinsonABWilliamsGT. 1996. The Epstein-Barr virus gene BHRF1, a homologue of the cellular oncogene Bcl-2, inhibits apoptosis induced by gamma radiation and chemotherapeutic drugs. Adv Exp Med Biol406:83–97.
58.
MeiYPZhuXFZhouJMHuangHDengRZengYX. 2006. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Lett232:189–98.
59.
Michałowska-WenderGWenderM. 2006. Mononuclear subsets in the peripheral blood of multiple sclerosis patients in relation to results of brain gadolinium-enhancing imaging. Folia Neuropathol44:67–71.
60.
MungerKLLevinLIHollisBWHowardNSAscherioA. 2006. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA296:2832–8.
61.
MungerKLZhangSMO’ReillyEHernánMAOlekMJWillettWC and others. 2004. Vitamin D intake and incidence of multiple sclerosis. Neurology62:60–5.
62.
NemerowGRMoldCSchwendVKTollefsonVCooperNR. 1987. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol61:1416–20.
63.
NonneckeBJFranklinSTReinhardtTAHorstRL. 1993. In vitro modulation of proliferation and phenotype of resting and mitogen-stimulated bovine mononuclear leukocytes by 1,25-dihydroxyvitamin D3. Vet Immunol Immunopathol38:75–89.
64.
PeferoenLANLamersFLodderLNRGerritsenWHHuitingaIMeliefJ and others. 2010. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain133:e137.
65.
PenderMP. 1998. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet351:978–81.
66.
PenderMP. 2003. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol24:584–8.
67.
PenderMP. 2009a. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev8:563–568.
68.
PenderMP. 2009b. Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis?Brain132:3196–8.
69.
PenderMPCsurhesPALenarczykAPflugerCMMBurrowsSR. 2009. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry80:498–505.
70.
PenderMPGreerJM. 2007. Immunology of multiple sclerosis. Curr Allergy Asthma Rep7:285–92.
71.
PohlDKroneBRostasyKKahlerEBrunnerELehnertM and others. 2006. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology67:2063–5.
72.
PudneyVALeeseAMRickinsonABHislopAD. 2005. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med201:349–60.
73.
RandKHHouckHDenslowNDHeilmanKM. 2000. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci173:32–9.
74.
RastelliJHömig-HölzelCSeagalJMüllerWHermannACRajewskyK and others. 2008. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood111:1448–55.
75.
ReiberHLangeP. 1991. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem37:1153–60.
76.
ReinherzELWeinerHLHauserSLCohenJADistasoJASchlossmanSF. 1980. Loss of suppressor T cells in active multiple sclerosis: analysis with monoclonal antibodies. N Engl J Med303:125–9.
77.
RickinsonABKieffE. 2001. Epstein-Barr virus. In: KnipeDMHowleyPM editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins. p 2575–627.
78.
RoughanJEThorley-LawsonDA. 2009. The intersection of Epstein-Barr virus with the germinal center. J Virol83:3968–76.
79.
RoughanJETorgborCThorley-LawsonDA. 2010. Germinal center B cells latently infected with Epstein-Barr virus proliferate extensively but do not increase in number. J Virol84:1158–68.
80.
SavoldoBGossJAHammerMMZhangLLopezTGeeAP and others. 2006. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood108:2942–9.
81.
SerafiniBRosicarelliBFranciottaDMagliozziRReynoldsRCinqueP and others. 2007. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med204:2899–912.
82.
SerafiniBSeveraMColumba-CabezasSRosicarelliBVeroniCChiappettaG and others. 2010. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol69:677–93.
83.
SibleyWABamfordCRClarkK. 1985. Clinical viral infections and multiple sclerosis. Lancet325:1313–5.
84.
SimonKCYangXMungerKLAscherioA. 2007. Variation in the Epstein-Barr virus receptor, CR2, and risk of multiple sclerosis. Multiple Sclerosis13:947–8.
85.
SmetsFLatinneDBazinHRedingROtteJBButsJP and others. 2002. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation73:1603–10.
86.
SokalEMHoppenbrouwersKVandermeulenCMoutschenMLéonardPMoreelsA and others. 2007. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis196:1749–53.
87.
SospedraMMartinR. 2005. Immunology of multiple sclerosis. Annu Rev Immunol23:683–747.
88.
SouzaTAStollarBDSullivanJLLuzuriagaKThorley-LawsonDA. 2005. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A102:18093–8.
89.
StrowigTGurerCPlossALiuYArreyFSashiharaJ and others. 2009. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med206:1423–34.
90.
SumayaCVMyersLWEllisonGW. 1980. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol37:94–6.
91.
SumayaCVMyersLWEllisonGWEnchY. 1985. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol17:371–7.
92.
SundströmPJutoPWadellGHallmansGSvenningssonANyströmL and others. 2004. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology62:2277–82.
93.
TabiZMcCombePAPenderMP. 1994. Apoptotic elimination of Vb8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of Vb8.2+ encephalitogenic T cells. Eur J Immunol24:2609–17.
94.
ThackerELMirzaeiFAscherioA. 2006. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol59:499–503.
95.
ThompsonAJBrazilJWhelanCAMartinEAHutchinsonMFeigheryC. 1986. Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?J Neurol Neurosurg Psychiatry49:905–12.
96.
Thorley-LawsonDAGrossA. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med350:1328–37.
97.
TourtellotteWWPotvinARBaumhefnerRWPotvinJHMaBISyndulkoK and others. 1980. Multiple sclerosis de novo CNS IgG synthesis: effect of CNS irradiation. Arch Neurol37:620–4.
98.
TrotterJLCliffordDBMcInnisJEGriffethRCBrunsKAPerlmutterMS and others. 1989. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol25:172–8.
99.
TynanFEElhassenDPurcellAWBurrowsJMBorgNAMilesJJ and others. 2005. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J Exp Med202:1249–60.
100.
UlettG. 1948. Geographic distribution of multiple sclerosis. Dis Nerv Syst9:342–6.
101.
Van NoortJMBajramovicJJPlompACvan StipdonkMJB. 2000. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol105:46–57.
102.
Van SechelACBajramovicJJvan StipdonkMJBPersoon-DeenCGeutskensSBvan NoortJM. 1999. EBV-induced expression and HLA-DR-restricted presentation by human B cells of aB-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol162:129–35.
103.
VeldmanCMCantornaMTDeLucaHF. 2000. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys374:334–8.
WandingerK-PJabsWSiekhausABubelSTrillenbergPWagnerH-J and others. 2000. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology55:178–84.
106.
WardemannHYurasovSSchaeferAYoungJWMeffreENussenzweigMC. 2003. Predominant autoantibody production by early human B cell precursors. Science301:1374–77.
107.
WarnerHBCarpRI. 1981. Multiple sclerosis and Epstein-Barr virus. Lancet318:1290.
108.
WillisSNStadelmannCRodigSJCaronTGattenloehnerSMallozziSS and others. 2009. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain132:3318–28.
109.
YajimaMImadomeKNakagawaAWatanabeSTerashimaKNakamuraH and others. 2008. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis198:673–82.
110.
ZivadinovRZorzonMWeinstock-GuttmanBSerafinMBoscoABratinaA and others. 2009. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J Neurol, Neurosurg Psychiatry80:620–5.
111.
ŽofkováIKanchevaRL. 1997. The effect of 1,25(OH)2 vitamin D3 on CD4+/CD8+ subsets of T lymphocytes in postmenopausal women. Life Sci61:147–52.
